CLINICAL TRIAL OF A NOVEL ANTIHIV OLIGONUCLEOTIDE

Information

• Research Project
• 2672615

• ApplicationId

  2672615

• Core Project Number

  R44AI038788

• Full Project Number

  5R44AI038788-03

• Serial Number

  38788

• FOA Number

• Sub Project Id

• Project Start Date

  9/1/1995 - 29 years ago

• Project End Date

  9/29/1999 - 25 years ago

• Program Officer Name

• Budget Start Date

  9/30/1998 - 26 years ago

• Budget End Date

  9/29/1999 - 25 years ago

• Fiscal Year

  1998

• Support Year

  3

• Suffix

• Award Notice Date

  9/29/1998 - 26 years ago

Organizations

• ARONEX PHARMACEUTICALS, INC. C/O ANTIGENICS, INC

The long term objective of this work is to determine the efficacy of a novel oligonucleotide drug (AR177) against HIV in humans. The primary aim of this grant is to perform a Phase Ib, multiple-dose clinical trial of AR177. Other aims are to perform a pharmacokinetic analysis of AR177 in the patient plasma from the Phase Ib clinical trial, and to determine the binding of AR177 to key blood constituents in vitro.

IC Name

• Activity

  R44

• Administering IC

  AI

• Application Type

  5

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  856

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  ZRG5

• Study Section Name

• Organization Name

  ARONEX PHARMACEUTICALS, INC.

• Organization Department

• Organization DUNS

• Organization City

  THE WOODLANDS

• Organization State

  TX

• Organization Country

  UNITED STATES

• Organization Zip Code

  77380

• Organization District

  UNITED STATES